Quantum Biopharma (QNTM) EBIAT (2019 - 2026)

Quantum Biopharma has disclosed EBIAT across 8 years of filings, most recently posting -$3.0 million for Q1 2026.

• EBIAT for Q1 2026 came in at -$3.0 million, up 66.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.2 million (down 339.96% YoY), and the FY2025 annual result was -$27.0 million, down 80.73% from the prior year.
• EBIAT came in at -$3.0 million for Q1 2026 at Quantum Biopharma, down from -$2.5 million in the prior quarter.
• In the past five years, EBIAT ranged from a high of $8.0 million in Q2 2022 to a low of -$47.3 million in Q4 2022.
• The 5-year median for EBIAT is -$2.1 million (2024), against an average of -$5.0 million.
• Across the five-year window, EBIAT soared 254.96% in 2024 and plunged 317.89% in 2025, its largest moves.
• Quantum Biopharma's EBIAT stood at -$47.3 million in 2022, then climbed by 26.34% to -$34.8 million in 2023, then jumped by 93.99% to -$2.1 million in 2024, then dropped by 21.04% to -$2.5 million in 2025, then retreated by 17.18% to -$3.0 million in 2026.
• The last three EBIAT figures came in at -$3.0 million (Q1 2026), -$2.5 million (Q4 2025), and -$4.8 million (Q3 2025), per Business Quant data.